BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July

Day

• 1
• 2
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 19
• 20
• 21
• 22
• 23
• 26
• 27
• 28
• 29
• 30

• Press Releases

  Integrated Biosciences Appoints Daniel J. Anderson, Ph.D. as Chief Scientific Officer

  January 27, 2026

   · 

  2 min read
• 

  Legal

  CytoDyn’s Former CEO Gets Jail Time, $5.3M+ Fine for Securities Fraud

  Nader Pourhassan, who led CytoDyn for nearly 10 years, was convicted in December 2024 of misleading investors regarding the biotech’s investigational COVID-19 and HIV drug, which artificially inflated its share price.

  January 27, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  GLP-1

  Baseline Debuts To Challenge GLP-1 Giant Lilly in Alcohol Use Disorder

  While Baseline Therapeutics declined to disclose its starting capital, the startup said it will use the funds to push its GLP-1 asset BT-001 into late-stage development, with two trials planned this year.

  January 27, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Inflammatory bowel disease

  Boehringer Commits up to $1.26B in IBD Pact With China’s Simcere

  The cornerstone of the deal is SIM0709, which Simcere designed to target both TL1A and IL-23, crucial players in facilitating inflammation. Boehringer Ingelheim will advance the asset for inflammatory bowel diseases.

  January 27, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  GLP-1

  Roche’s 22% Weight Loss Benefit Seals GLP-1’s Phase III Plans, Boosts Zealand Combo

  Roche said the Phase II results help build the case for advancing CT-388 into late-stage testing, which is set to get underway this quarter.

  January 27, 2026

   · 

  2 min read

   · 

  Annalee Armstrong
• 

  Gene editing

  FDA Lifts One of Two Clinical Holds on Intellia’s ATTR Gene Editing Program

  After a patient safety signal and then death, the FDA in October 2025 placed holds on two of the company’s CRISPR programs for hereditary transthyretin amyloidosis.

  January 27, 2026

   · 

  2 min read

   · 

  Dan Samorodnitsky
• Press Releases

  Signios Bio Launches Xenium 5K Spatial Transcriptomics Grant Program in Collaboration with 10x Genomics

  January 27, 2026

   · 

  2 min read
• Press Releases

  Retinal Disease Expert Dr. Taiji Sakamoto Joins Kiora Pharmaceuticals’ Scientific Advisory Board

  January 27, 2026

   · 

  1 min read